Journal Information
Vol. 51. Issue 7.
Pages 360 (July 2015)
Letter to the Editor
Full text access
2014 GesEPOC and Systemic Steroids in Chronic Obstructive Pulmonary Disease (COPD) Exacerbation: An Update
Actualización de GesEPOC 2014 y corticoides sistémicos en la agudización de enfermedad pulmonar obstructiva crónica (EPOC)
Visits
...
Pedro J. Marcosa,
Corresponding author
, Arturo Huertab, Eduardo Márquez-Martínc
a Servicio de Neumología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña(CHUAC), SERGAS, A Coruña, Spain
b Imperial College London Academic Unit of Respiratory Medicine at Royal Brompton Hospital, London, United Kingdom
c Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Virgen del Rocío, Sevilla, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
To the Editor,

We have read the latest version of the Spanish guidelines on COPD (GesEPOC), published recently (January 2014) in Archivos de Bronconeumología.1 When the AUDIEPOC study was published in July 2012, we observed that there was little homogeneity in the management of COPD exacerbation at the national level.2 A more rigorous review of the published data revealed that this variability also exists in the use of systemic corticosteroids during exacerbations. In the 2014 update, GesEPOC clinical guidelines propose a change in systemic corticosteroid treatment during exacerbations. Thus, the original version recommended a short course of 7–10 days,3 while in the 2014 update, the guidelines support the use of “short 5-day courses for […] exacerbations that do not require hospitalization”.

We believe that this change is based essentially on data from the REDUCE clinical trial,4 which compared treatment with a short 5-day course of 40mg of prednisone versus a 14-day course during exacerbations. The trial showed a similar reexacerbation rate, with the advantage of lower exposure to corticosteroids and very similar findings as regards outcomes (hospital stay and deaths).

We agree that exacerbations can be managed with lower doses and shorter treatment times than those used in routine clinical practice. At the same time, we consider that this conclusion, currently limited by the guidelines to outpatients, could also be extended to some patients with more severe exacerbations who require hospital admission. In the REDUCE clinical trial, of the 314 patients who attended the Emergency Department (311 evaluated) and were randomized to receive a short or long corticosteroid regimen, 289 (92%) patients were admitted to hospital. The groups were adequately balanced with respect to COPD severity (GOLD 2, 3 and 4 in both groups) and clinical presentation (vital signs, oxygenation on admission, leukocytosis).

The meta-analysis published by Cheng et al.5 also reinforces the hypothesis that lower doses of corticosteroids (30–80mg of prednisolone for 5 days) can be safely used in inpatients with COPD exacerbation.

This meta-analysis and the REDUCE clinical trial are perhaps the only studies to support short in-hospital regimens, and further research will probably be required to confirm this in special populations (e.g. patients with persistent bronchospasm). However, we consider that GesEPOC guidelines should include this patient population, and indicate that this treatment regimen is not limited to outpatients treated for COPD exacerbation.

References
[1]
M. Miravitlles, J.J. Soler-Cataluña, M.D. Calle, J. Molina, P. Almagro, J.A. Quintano, et al.
Guía Española de la EPOC (GesEPOC). Actualización.
Arch Bronconeumol, 50 (2014), pp. 1-16
[2]
F. Pozo-Rodríguez, J.L. López-Campos, C.J. Alvarez-Martínez, A. Castro-Acosta, R. Agüero, J. Hueto, AUDIPOC Study Group, et al.
Clinical audit of COPD patients requiring hospital admissions in Spain: AUDIPOC study.
[3]
Guía de práctica clínica para el diagnóstico y tratamiento de pacientes con enfermedad pulmonar obstructiva crónica (EPOC)-Guía Española de la EPOC (GesEPOC).
Arch Bronconeumol, 48 (2012), pp. 2-58
[4]
J.D. Leuppi, P. Schuetz, R. Bingisser, M. Bodmer, M. Briel, T. Drescher, et al.
Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease.
JAMA, 309 (2013), pp. 2223-2231
[5]
T. Cheng, Y. Gong, Y. Guo, Q. Cheng, M. Zhou, G. Shi, et al.
Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta-analysis of randomized controlled trials.
Clin Respir J, 7 (2013), pp. 305-318

Please cite this article as: Marcos PJ, Huerta A, Márquez-Martín E. Actualización de GesEPOC 2014 y corticoides sistémicos en la agudización de enfermedad pulmonar obstructiva crónica (EPOC). Arch Bronconeumol. 2015;51:360.

Copyright © 2014. SEPAR
Archivos de Bronconeumología

Subscribe to our newsletter

Article options
Tools

Are you a health professional able to prescribe or dispense drugs?